Table 1.
Model | Benefits | Drawbacks | Key Findings | |
---|---|---|---|---|
Humans | Human cross-sectional and prospective studies Refs 9–13, 18, 19 | Directly applicable to aging and disease populations, including AD | Only correlative evidence | Greater large artery stiffness is correlated with:
|
Rodent models: direct modulation of arterial stiffness | Elastin haploinsufficient: Heterozygote Eln deletion (full knockout of Eln not viable). Refs 35–37 |
|
|
Greater large artery stiffness leads to:
|
Fibrillin-1 mutation: Heterozygote mutation of fribrillin-1, Fbn1C1039G/+. A model of Marfan Syndrome. Ref 39 | Targeted increase in arterial extracellular matrix stiffness |
|
Greater large artery stiffness leads to:
|
|
Carotid artery calcification: Mice studied 2–3 wk after application of calcium chloride to the carotid artery. Refs 28, 42, 43 |
|
An acute, dramatic increase in arterial stiffness that does not model the gradual process of arterial stiffening with human aging. | Increased carotid artery stiffness leads to:
|
|
Cross-link breakers: ALT-711 (Alagebrium) treatment typically for 4–8 wk. Ref 46 | Reduces large artery stiffness (unlike other rodent models of increased stiffness) |
|
Reduced large artery stiffness leads to:
|
|
Rodent model associated with greater pulse pressure | Transverse aortic constriction (TAC): Constriction resulting from suture tied around the aortic arch, usually between the right and left carotid artery branches. Refs 17, 22, 50 |
|
|
Increased carotid artery pulse pressure leads to:
|
Aβ, amyloid-β; AD, Alzheimer’s disease; BBB, blood-brain barrier; MCI, mild cognitive impairment.